COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE BLADDER

被引：0
|
作者：
Malone, D. C. [1 ]
Armstrong, E. P. [1 ]
Bui, C. [2 ]
机构：
[1] Univ Arizona, Tucson, AZ USA
[2] Astellas Pharma US Inc, Deerfield, IL USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.838
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A155 / A155
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States
    Chen, Jing Voon
    Klein, Timothy M.
    Nesheim, Jeffrey
    Mudd, Paul N., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1092 - 1100
  • [2] Cost-effectiveness of novel therapies for overactive bladder
    Mayr, Craig A.
    Shepherd, Jonathan P.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (04) : 527 - 535
  • [3] COST-EFFECTIVENESS OF MIRABEGRON VERSUS ANTIMUSCARINICS FOR THE TREATMENT OF OVERACTIVE BLADDER IN ARGENTINA
    Ramos, B.
    Sanchez Trujillo, L. A.
    Walker, D.
    Anaya, P.
    VALUE IN HEALTH, 2020, 23 : S378 - S378
  • [4] Fesoterodine for the treatment of overactive bladder -: A cost-effectiveness case study of Sweden
    Prutz, C.
    Snedecor, S.
    Botteman, M.
    Trocio, J.
    Weinstein, D.
    VALUE IN HEALTH, 2008, 11 (03) : A302 - A302
  • [5] Cost-effectiveness of tolterodine, a new treatment for symptoms of overactive bladder.
    Kobelt, G
    Jonsson, L
    Lund, AM
    JOURNAL OF UROLOGY, 1998, 159 (05): : 302 - 302
  • [6] A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) : 629 - 630
  • [7] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Jonathan P. Shepherd
    Charelle M. Carter-Brooks
    Christopher Chermanksy
    International Urogynecology Journal, 2018, 29 : 1213 - 1219
  • [8] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Shepherd, Jonathan P.
    Carter-Brooks, Charelle M.
    Chermanksy, Christopher
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1213 - 1219
  • [9] COST-EFFECTIVENESS OF TOLTERODINE AS TREATMENT FOR OVERACTIVE BLADDER (OAB) IN ADULT MEXICAN PATIENTS
    Arreola-Ornelas, H.
    Rosado-Buzzo, A.
    Garcia-Mollinedo, M.
    Camacho-Cordero, L.
    Mucino-Ortega, E.
    Mould-Quevedo, J. F.
    Galindo-Suarez, R. M.
    VALUE IN HEALTH, 2011, 14 (03) : A76 - A76
  • [10] Cost-Effectiveness of Third-Line Therapies for Overactive Bladder
    Cohen S.A.
    Current Bladder Dysfunction Reports, 2018, 13 (3) : 153 - 157
12345